Sponsor or institution
Clinical trials and research at Kumquat Biosciences Inc.
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Kumquat Biosciences Inc. that are recruiting, in United States. By phase: Phase 1 (4), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| KQB368 as a single-drug treatment for adults with advanced solid tumors | Phase 1 | Los Angeles, California and 13 other locations | Recruiting | Apr 21, 2026 |
| KQB198 plus imatinib for first-line advanced or metastatic GIST | Phase 2 | Los Angeles, California and 16 other locations | Recruiting | Feb 12, 2026 |
| KQB548 for advanced solid tumors with a KRAS G12D mutation | Phase 1 | La Jolla, California and 12 other locations | Recruiting | Oct 6, 2025 |
| KQB168 alone or with pembrolizumab for adults with advanced solid tumors | Phase 1 | Phoenix, Arizona and 14 other locations | Recruiting | May 29, 2025 |
| Investigating KQB365 for treating advanced solid tumors | Phase 1 | Phoenix, Arizona and 10 other locations | Recruiting | Dec 6, 2024 |
All recruiting trials (5)
-
KQB368 as a single-drug treatment for adults with advanced solid tumors
This study tests whether taking KQB368 by mouth every day can help shrink tumors and is safe for adults with advanced solid cancers.
-
KQB198 plus imatinib for first-line advanced or metastatic GIST
This Phase 2 test will see if adding the experimental drug KQB198 to imatinib helps people with advanced or metastatic GIST who are starting first-line treatment.
-
KQB548 for advanced solid tumors with a KRAS G12D mutation
This trial will test whether KQB548 can shrink tumors and is safe in adults with advanced pancreatic, colorectal, or non-small cell lung cancer that have a KRAS G12D mutation after prior therapy.
-
KQB168 alone or with pembrolizumab for adults with advanced solid tumors
This will test whether daily KQB168, alone or together with pembrolizumab, can shrink tumors and is safe for adults with advanced solid cancers that have progressed after prior immunotherapy.
-
Investigating KQB365 for treating advanced solid tumors
This study tests if a new treatment called KQB365, alone or with another drug, can help adults with advanced solid tumors that have specific genetic mutations.
Quick answers
How many clinical trials run by Kumquat Biosciences Inc. are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 4, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.